Pharmaceutical Ethics serves as the guiding moral foundation that shapes the conduct and decision-making within the pharmaceutical industry. It is a crucial framework designed to ensure that drug development, production, and distribution align with the principles of patient welfare and societal well-being.
At its core, pharmaceutical ethics underscores the significance of placing patient interests above commercial considerations. This involves promoting fair pricing, ensuring accessibility, and facilitating the equitable distribution of pharmaceutical products to enhance global health outcomes.
The ethical dimensions of pharmaceutical practices extend to the responsible marketing and promotion of drugs. This includes a commitment to accurate and unbiased promotional materials, coupled with ethical engagements with healthcare professionals to prevent undue influence. Upholding the highest standards of integrity is paramount for maintaining public trust and confidence in the industry.
Furthermore, pharmaceutical ethics delicately navigates the intersection of advancing scientific knowledge and safeguarding human rights. It acts as a moral compass, directing the industry toward practices that prioritize patient well-being, uphold integrity, and contribute positively to global health.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico